We serve 2-Bromo-4-(trifluoromethyl)phenol CAS:81107-97-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Contact us for information like 2-Bromo-4-(trifluoromethyl)phenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Bromo-4-(trifluoromethyl)phenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Bromo-4-(trifluoromethyl)phenol Use and application,2-Bromo-4-(trifluoromethyl)phenol technical grade,usp/ep/jp grade.
Related News: According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017).2-Fluoro-3-methylaniline manufacturer f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national.2-Isopropyl-4-methyl thiazole supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.
